NE
Unclaimed author profile

Nelson Alvis‐Guzmán

· Lawrence Berkeley National Laboratory

Is this your research profile?

Create or sign in to your KnowledgeTrend account to claim this page. After the claim, this same profile URL and its linked publications will belong to your account. Claiming does not automatically grant a verified badge.

Create account and claim this profile Sign in to claim
10Linked publications
0Citations
0h-index
0i10-index

Metrics are calculated from publications currently linked to this profile.

Researcher overview

About

Nelson Alvis‐Guzmán is a registered researcher in their academic field.

Research output

Recent Publications

10 research works linked to this profile

▤
Cardiac Imaging and Diagnostics, Cardiac, Anesthesia and Surgical Outcomes, Pulmonary Hypertension Research and Treatments · 2023 · Journal of the American College of Cardiology

Global Burden of Cardiovascular Diseases and Risks, 1990-2022

George A. Mensah, Valentı́n Fuster, Christopher J L Murray, Gregory A. Roth, Yohannes Abate, Mohammadreza Abbasian, Foad Abd-Allah, Ashkan Abdollahi, Mohammad Abdollahı, Deldar Morad Abdulah, Auwal Abdullahi, Ayele Mamo Abebe, Aidin Abedi, Armita Abedi, Olugbenga Olusola Abiodun, Hiwa Abubaker Ali, Eman Abu‐Gharbieh, Niveen M. E. Abu-Rmeileh, Salahdein Aburuz, Abdelrahman Ibrahim Abushouk, Ahmed Abu‐Zaid, Tigist Demssew Adane, Nicola J. Adderley, Oladimeji Adebayo, Bashir Aden, Temitayo Esther Adeyeoluwa, Olorunsola Adeyomoye, Qorinah Estiningtyas Sakilah Adnani, Fatemeh Afrashteh, Shadi Afyouni, Saira Afzal, Pradyumna Agasthi, Antonella Agodi, Constanza Elizabeth Aguilera Arriagada, Williams Agyemang‐Duah, Bright Opoku Ahinkorah, Aqeel Ahmad, Danish Ahmad, Firdos Ahmad, Muayyad Ahmad, Ayman Ahmed, Haroon Ahmed, Muktar Beshir Ahmed, Syed Anees Ahmed, Marjan Ajami, Karolina Akinosoglou, Moein Ala, Tareq Mohammed Ali AL-Ahdal, Samer O Alalalmeh, Ziyad Al‐Aly, Nazmul Alam, Rasmieh Al‐Amer, Alaa Alashi, Mohammed ALBashtawy, Mohammad T AlBataineh, Haileselasie Berhane Alema, Sharifullah Alemi, Megbaru Alemu, Adel Al‐Gheethi, Khalid F. AlHabib, Fadwa Alhalaiqa, Mohammed Usman Ali, Rafat Ali, Syed Shujait Ali, Gianfranco Alicandro, Reyhaneh Alikhani, Syed Mohamed Aljunid, François Alla, Wael Almahmeed, Sabah Al-Marwani, Jordi Alonso, Rajaa Al‐Raddadi, Farrukh Jawad Alvi, Nelson Alvis‐Guzmán, Nelson J Alvis-Zakzuk, Hassan Alwafi, Hany Aly, Prince M. Amegbor, Tarek Tawfik Amin, Alireza Amindarolzarbi, Mostafa Amini‐Rarani, Sohrab Amiri, Enrico Ammirati, Tanu Anand, Robert Ancuceanu, Deanna Anderlini, Abhishek Anil, Golnoosh Ansari, P.E. Anyanwu, Anayochukwu Edward Anyasodor, Geminn Louis Carace Apostol, Jalal Arabloo, Mosab Arafat, Aleksandr Y. Aravkin, Olatunde Aremu, Benedetta Armocida, Johan Ärnlöv, Oluwaseyi Olalekan Arowosegbe, Anton A Artamonov

▤
COVID-19 and healthcare impacts, Economic and Financial Impacts of Cancer, Global Cancer Incidence and Screening · 2021 · JAMA Oncology

Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019

Jonathan Kocarnik, Kelly Compton, Frances Dean, Weijia Fu, Brian Gaw, James Harvey, Hannah Henrikson, Dan Lu, Alyssa Pennini, Rixing Xu, Emad Ababneh, Mohsen Abbasi‐Kangevari, Hedayat Abbastabar, Sherief Abd‐Elsalam, Amir Abdoli, Aidin Abedi, Hassan Abidi, Hassan Abolhassani, Isaac Akinkunmi Adedeji, Qorinah Estiningtyas Sakilah Adnani, Shailesh M Advani, Muhammad U. Afzal, Mohammad Aghaali, Bright Opoku Ahinkorah, Sajjad Ahmad, Tauseef Ahmad, Ali Ahmadi, Sepideh Ahmadi, Tarik A. Rashid, Yusra Ahmed Salih, Gizachew Taddesse Akalu, Addis Aklilu, Tayyaba Akram, Chisom Joyqueenet Akunna, Hanadi Al Hamad, Fares Alahdab, Ziyad Al‐Aly, Saqib Ali, Yousef Alimohamadi, Vahid Alipour, Syed Mohamed Aljunid, Motasem Alkhayyat, Amir Almasi‐Hashiani, Nihad A. Almasri, Sadeq Ali Al‐Maweri, Sami Almustanyir, Nivaldo Alonso, Nelson Alvis‐Guzmán, Hubert Amu, Etsay Woldu Anbesu, Robert Ancuceanu, Fereshteh Ansari, Alireza Ansari‐Moghaddam, Maxwell Hubert Antwi, Davood Anvari, Anayochukwu Edward Anyasodor, Muhammad Aqeel, Jalal Arabloo, Morteza Arab‐Zozani, Olatunde Aremu, Hany Ariffin, Timur Aripov, Muhammad Arshad, Al Artaman, Judie Arulappan, Zatollah Asemi, Mohammad Asghari Jafarabadi, Tahira Ashraf, Prince Atorkey, Avinash Aujayeb, Marcel Ausloos, Atalel Fentahun Awedew, Beatriz Paulina Ayala Quintanilla, Temesgen Ayenew, Mohammed A. Azab, Sina Azadnajafabad, Amirhossein Azari Jafari, Ghasem Azarian, Ahmed Y. Azzam, Ashish Badiye, Saeed Bahadory, Atif Amin Baig, Jennifer L. Baker, Senthilkumar Balakrishnan, Maciej Banach, Till Bärnighausen, Francesco Barone‐Adesi, Fabio Barra, Amadou Barrow, Masoud Behzadifar, Uzma Belgaumi, Woldesellassie Bezabhe, Yihienew Mequanint Bezabih, Devidas S. Bhagat, Akshaya Srikanth Bhagavathula, Nikha Bhardwaj, Pankaj Bhardwaj, Sonu Bhaskar, Krittika Bhattacharyya, Vijayalakshmi S Bhojaraja

IMPORTANCE: The Global Burden of Diseases, Injuries, and Risk Factors Study 2019 (GBD 2019) provided systematic estimates of incidence, morbidity, and mortality to inform local and international efforts toward reducing cancer burden. OBJECTIVE: To estimate cancer burden and trends globally for 204 countries and territories and by Sociodemographic Index (SDI) quintiles from 2010 to 2019. EVIDENCE REVIEW: The GBD 2019 estimation methods were used to describe cancer incidence, mortality, years lived with disability, years of life lost, and disability-adjusted life years (DALYs) in 2019 and over the past decade. Estimates are also provided by quintiles of the SDI, a composite measure of educational attainment, income per capita, and total fertility rate for those younger than 25 years. Estimates include 95% uncertainty intervals (UIs). FINDINGS: In 2019, there were an estimated 23.6 million (95% UI, 22.2-24.9 million) new cancer cases (17.2 million when excluding nonmelanoma skin cancer) and 10.0 million (95% UI, 9.36-10.6 million) cancer deaths globally, with an estimated 250 million (235-264 million) DALYs due to cancer. Since 2010, these represented a 26.3% (95% UI, 20.3%-32.3%) increase in new cases, a 20.9% (95% UI, 14.2%-27.6%) increase in deaths, and a 16.0% (95% UI, 9.3%-22.8%) increase in DALYs. Among 22 groups of diseases and injuries in the GBD 2019 study, cancer was second only to cardiovascular diseases for the number of deaths, years of life lost, and DALYs globally in 2019. Cancer burden differed across SDI quintiles. The proportion of years lived with disability that contributed to DALYs increased with SDI, ranging from 1.4% (1.1%-1.8%) in the low SDI quintile to 5.7% (4.2%-7.1%) in the high SDI quintile. While the high SDI quintile had the highest number of new cases in 2019, the middle SDI quintile had the highest number of cancer deaths and DALYs. From 2010 to 2019, the largest percentage increase in the numbers of cases and deaths occurred in the low and low-middle SDI quintiles. CONCLUSIONS AND RELEVANCE: The results of this systematic analysis suggest that the global burden of cancer is substantial and growing, with burden differing by SDI. These results provide comprehensive and comparable estimates that can potentially inform efforts toward equitable cancer control around the world.

▤
Global Cancer Incidence and Screening, COVID-19 and healthcare impacts, Hematological disorders and diagnostics · 2019 · JAMA Oncology

Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017

Christina Fitzmaurice, Degu Abate, Naghmeh Abbasi, Hedayat Abbastabar, Foad Abd-Allah, Omar Abdel‐Rahman, Ahmed Abdelalim, Amir Abdoli, Ibrahim Abdollahpour, Abdishakur S. M. Abdulle, Nebiyu Dereje Abebe, Haftom Niguse Abraha, Laith J. Abu‐Raddad, Ahmed Abualhasan, Isaac Akinkunmi Adedeji, Shailesh M Advani, Mohsen Afarideh, Mahdi Afshari, Mohammad Aghaali, Dominic Agius, Sutapa Agrawal, Ayat Ahmadi, Elham Ahmadian, Ehsan Ahmadpour, Muktar Beshir Ahmed, Mohammad Esmaeil Akbari, Tomi Akinyemiju, Ziyad Al‐Aly, Assim M. AlAbdulKader, Fares Alahdab, Shazia Alam, Genet Melak Alamene, Birhan Alemnew, Kefyalew Addis Alene, Cyrus Alinia, Vahid Alipour, Syed Mohamed Aljunid, Fatemeh Allah Bakeshei, Majid A. Almadi, Amir Almasi‐Hashiani, Ubai Alsharif, Shirina Alsowaidi, Nelson Alvis‐Guzmán, Erfan Amini, Saeed Amini, Yaw Ampem Amoako, Zohreh Anbari, Nahla Anber, Cătălina Liliana Andrei, Mina Anjomshoa, Fereshteh Ansari, Ansariadi Ansariadi, Seth Christopher Yaw Appiah, Morteza Arab‐Zozani, Jalal Arabloo, Zohreh Arefi, Olatunde Aremu, Habtamu Abera Areri, Al Artaman, Hamid Asayesh, Ephrem Tsegay Asfaw, Alebachew Fasil Ashagre, Reza Assadi, Bahar Ataeinia, Hagos Tasew Atalay, Zerihun Ataro, Suleman Atique, Marcel Ausloos, Leticia Ávila‐Burgos, Euripide Avokpaho, Ashish Awasthi, Nefsu Awoke, Beatriz Paulina Ayala Quintanilla, Martin Amogre Ayanore, Henok Tadesse Ayele, Ebrahim Babaee, Umar Bacha, Alaa Badawi, Mojtaba Bagherzadeh, Eleni Bagli, Senthilkumar Balakrishnan, Abbas Balouchi, Till Bärnighausen, Robert J. Battista, Masoud Behzadifar, Meysam Behzadifar, Bayu Begashaw Bekele, Yared Belete Belay, Yaschilal Muche Belayneh, Kathleen Berfield, Adugnaw Berhane, Eduardo Bernabé, Mircea Beuran, Nickhill Bhakta, Krittika Bhattacharyya, Belete Biadgo, Ali Bijani, Muhammad Shahdaat Bin Sayeed, Charles Birungi, Catherine Bisignano

Importance Cancer and other noncommunicable diseases (NCDs) are now widely recognized as a threat to global development. The latest United Nations high-level meeting on NCDs reaffirmed this observation and also highlighted the slow progress in meeting the 2011 Political Declaration on the Prevention and Control of Noncommunicable Diseases and the third Sustainable Development Goal. Lack of situational analyses, priority setting, and budgeting have been identified as major obstacles in achieving these goals. All of these have in common that they require information on the local cancer epidemiology. The Global Burden of Disease (GBD) study is uniquely poised to provide these crucial data. Objective To describe cancer burden for 29 cancer groups in 195 countries from 1990 through 2017 to provide data needed for cancer control planning. Evidence Review We used the GBD study estimation methods to describe cancer incidence, mortality, years lived with disability, years of life lost, and disability-adjusted life-years (DALYs). Results are presented at the national level as well as by Socio-demographic Index (SDI), a composite indicator of income, educational attainment, and total fertility rate. We also analyzed the influence of the epidemiological vs the demographic transition on cancer incidence. Findings In 2017, there were 24.5 million incident cancer cases worldwide (16.8 million without nonmelanoma skin cancer [NMSC]) and 9.6 million cancer deaths. The majority of cancer DALYs came from years of life lost (97%), and only 3% came from years lived with disability. The odds of developing cancer were the lowest in the low SDI quintile (1 in 7) and the highest in the high SDI quintile (1 in 2) for both sexes. In 2017, the most common incident cancers in men were NMSC (4.3 million incident cases); tracheal, bronchus, and lung (TBL) cancer (1.5 million incident cases); and prostate cancer (1.3 million incident cases). The most common causes of cancer deaths and DALYs for men were TBL cancer (1.3 million deaths and 28.4 million DALYs), liver cancer (572 000 deaths and 15.2 million DALYs), and stomach cancer (542 000 deaths and 12.2 million DALYs). For women in 2017, the most common incident cancers were NMSC (3.3 million incident cases), breast cancer (1.9 million incident cases), and colorectal cancer (819 000 incident cases). The leading causes of cancer deaths and DALYs for women were breast cancer (601 000 deaths and 17.4 million DALYs), TBL cancer (596 000 deaths and 12.6 million DALYs), and colorectal cancer (414 000 deaths and 8.3 million DALYs). Conclusions and Relevance The national epidemiological profiles of cancer burden in the GBD study show large heterogeneities, which are a reflection of different exposures to risk factors, economic settings, lifestyles, and access to care and screening. The GBD study can be used by policy makers and other stakeholders to develop and improve national and local cancer control in order to achieve the global targets and improve equity in cancer care.

▤
Global Cancer Incidence and Screening, Multiple and Secondary Primary Cancers, Cancer Risks and Factors · 2018 · JAMA Oncology

Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016

Christina Fitzmaurice, Tomi Akinyemiju, Faris Lami, Shazia Alam, Reza Alizadeh‐Navaei, Christine A. Allen, Ubai Alsharif, Nelson Alvis‐Guzmán, Erfan Amini, Benjamin O. Anderson, Olatunde Aremu, Al Artaman, Solomon Weldegebreal Asgedom, Reza Assadi, Tesfay Mehari Atey, Leticia Ávila‐Burgos, Ashish Awasthi, Huda Omer Ba Saleem, Aleksandra Barać, James R. Bennett, Isabela M. Benseñor, Nickhill Bhakta, Hermann Brenner, Lucero Cahuana-Hurtado, Carlos A Castañeda-Orjuela, Ferrán Catalá-López, Jee-Young J Choi, Devasahayam Jesudas Christopher, Sheng‐Chia Chung, María Paula Curado, Lalit Dandona, Rakhi Dandona, José das Neves, Subhojit Dey, Samath Dhamminda Dharmaratne, David Teye Doku, Tim Driscoll, Manisha Dubey, Hedyeh Ebrahimi, Dumessa Edessa, Ziad El‐Khatib, Aman Yesuf Endries, Florian Fischer, Lisa M Force, Kyle J Foreman, Solomon Weldemariam Gebrehiwot, Sameer Vali Gopalani, Giuseppe Grosso, Rahul Gupta, Bishal Gyawali, Randah R Hamadeh, Samer Hamidi, James Harvey, Hamid Yimam Hassen, Roderick J. Hay, Simon I Hay, Behzad Heibati, Molla Kahssay Hiluf, Nobuyuki Horita, Hung Chak Ho, Olayinka Stephen Ilesanmi, Kaire Innos, Farhad Islami, Mihajlo Jakovljević, Sarah Charlotte Johnson, Jost B Jonas, Amir Kasaeian, Tesfaye Kassa, Yousef Khader, Ejaz Ahmad Khan, Gulfaraz Khan, Young‐Ho Khang, Mohammad Hossein Khosravi, Jagdish Khubchandani, Jacek A Kopec, G Anil Kumar, Michael Kutz, Deepesh Lad, Alessandra Lafranconi, Qing Lan, Yirga Legesse, James Leigh, Shai Linn, Raimundas Lunevičius, Azeem Majeed, Reza Malekzadeh, Déborah Carvalho Malta, LG Mantovani, Brian J. McMahon, Toni Meier, Yohannes Adama Melaku, Mulugeta Melku, Peter Memiah, Walter Mendoza, Tuomo J Meretoja, Haftay Berhane Mezgebe, Ted R. Miller, Shafiu Mohammed, Ali H. Mokdad, Mahmood Moosazadeh

Importance: The increasing burden due to cancer and other noncommunicable diseases poses a threat to human development, which has resulted in global political commitments reflected in the Sustainable Development Goals as well as the World Health Organization (WHO) Global Action Plan on Non-Communicable Diseases. To determine if these commitments have resulted in improved cancer control, quantitative assessments of the cancer burden are required. Objective: To assess the burden for 29 cancer groups over time to provide a framework for policy discussion, resource allocation, and research focus. Evidence Review: Cancer incidence, mortality, years lived with disability, years of life lost, and disability-adjusted life-years (DALYs) were evaluated for 195 countries and territories by age and sex using the Global Burden of Disease study estimation methods. Levels and trends were analyzed over time, as well as by the Sociodemographic Index (SDI). Changes in incident cases were categorized by changes due to epidemiological vs demographic transition. Findings: In 2016, there were 17.2 million cancer cases worldwide and 8.9 million deaths. Cancer cases increased by 28% between 2006 and 2016. The smallest increase was seen in high SDI countries. Globally, population aging contributed 17%; population growth, 12%; and changes in age-specific rates, -1% to this change. The most common incident cancer globally for men was prostate cancer (1.4 million cases). The leading cause of cancer deaths and DALYs was tracheal, bronchus, and lung cancer (1.2 million deaths and 25.4 million DALYs). For women, the most common incident cancer and the leading cause of cancer deaths and DALYs was breast cancer (1.7 million incident cases, 535 000 deaths, and 14.9 million DALYs). In 2016, cancer caused 213.2 million DALYs globally for both sexes combined. Between 2006 and 2016, the average annual age-standardized incidence rates for all cancers combined increased in 130 of 195 countries or territories, and the average annual age-standardized death rates decreased within that timeframe in 143 of 195 countries or territories. Conclusions and Relevance: Large disparities exist between countries in cancer incidence, deaths, and associated disability. Scaling up cancer prevention and ensuring universal access to cancer care are required for health equity and to fulfill the global commitments for noncommunicable disease and cancer control.

▤
Liver Disease Diagnosis and Treatment, Hepatitis B Virus Studies, Hepatocellular Carcinoma Treatment and Prognosis · 2017 · JAMA Oncology

The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level

Importance Liver cancer is among the leading causes of cancer deaths globally. The most common causes for liver cancer include hepatitis B virus (HBV) and hepatitis C virus (HCV) infection and alcohol use. Objective To report results of the Global Burden of Disease (GBD) 2015 study on primary liver cancer incidence, mortality, and disability-adjusted life-years (DALYs) for 195 countries or territories from 1990 to 2015, and present global, regional, and national estimates on the burden of liver cancer attributable to HBV, HCV, alcohol, and an “other” group that encompasses residual causes. Design, Settings, and Participants Mortality was estimated using vital registration and cancer registry data in an ensemble modeling approach. Single-cause mortality estimates were adjusted for all-cause mortality. Incidence was derived from mortality estimates and the mortality-to-incidence ratio. Through a systematic literature review, data on the proportions of liver cancer due to HBV, HCV, alcohol, and other causes were identified. Years of life lost were calculated by multiplying each death by a standard life expectancy. Prevalence was estimated using mortality-to-incidence ratio as surrogate for survival. Total prevalence was divided into 4 sequelae that were multiplied by disability weights to derive years lived with disability (YLDs). DALYs were the sum of years of life lost and YLDs. Main Outcomes and Measures Liver cancer mortality, incidence, YLDs, years of life lost, DALYs by etiology, age, sex, country, and year. Results There were 854 000 incident cases of liver cancer and 810 000 deaths globally in 2015, contributing to 20 578 000 DALYs. Cases of incident liver cancer increased by 75% between 1990 and 2015, of which 47% can be explained by changing population age structures, 35% by population growth, and −8% to changing age-specific incidence rates. The male-to-female ratio for age-standardized liver cancer mortality was 2.8. Globally, HBV accounted for 265 000 liver cancer deaths (33%), alcohol for 245 000 (30%), HCV for 167 000 (21%), and other causes for 133 000 (16%) deaths, with substantial variation between countries in the underlying etiologies. Conclusions and Relevance Liver cancer is among the leading causes of cancer deaths in many countries. Causes of liver cancer differ widely among populations. Our results show that most cases of liver cancer can be prevented through vaccination, antiviral treatment, safe blood transfusion and injection practices, as well as interventions to reduce excessive alcohol use. In line with the Sustainable Development Goals, the identification and elimination of risk factors for liver cancer will be required to achieve a sustained reduction in liver cancer burden. The GBD study can be used to guide these prevention efforts.

▤
Cardiovascular Health and Risk Factors, Diabetes, Cardiovascular Risks, and Lipoproteins, Cardiac Health and Mental Health · 2017 · Journal of the American College of Cardiology

Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015

Gregory A. Roth, Catherine O. Johnson, Amanuel Alemu Abajobir, Foad Abd-Allah, Semaw Ferede Abera, Gebre Yitayih Abyu, Muktar Beshir Ahmed, Baran Aksut, Shazia Alam, Khurshid Alam, François Alla, Nelson Alvis‐Guzmán, Stephen M. Amrock, Hossein Ansari, Johan Ärnlöv, Hamid Asayesh, Tesfay Mehari Atey, Leticia Ávila‐Burgos, Ashish Awasthi, Amitava Banerjee, Aleksandra Barać, Till Bärnighausen, Lars Barregård, Neeraj Bedi, Ezra B. Ketema, Derrick Bennett, Gebremedhin Berhe, Zulfiqar A Bhutta, Shimelash Bitew Workie, Jonathan R. Carapetis, Juan Jesús Carrero, Déborah Carvalho Malta, Carlos A Castañeda-Orjuela, Jacqueline Castillo-Rivas, Ferrán Catalá-López, Jee-Young Choi, Hanne Christensen, Massimo Círillo, Leslie T. Cooper, Michael H Criqui, David K Cundiff, Albertino Damasceno, Lalit Dandona, Rakhi Dandona, Kairat Davletov, Samath Dhamminda Dharmaratne, Prabhakaran Dorairaj, Manisha Dubey, Rebecca Ehrenkranz, Maysaa El Sayed Zaki, Emerito Jose A Faraon, Alireza Esteghamati, Talha Farid, Maryam S. Farvid, Valery L. Feigin, Eric L. Ding, Gerry Fowkes, Tsegaye Gebrehiwot, Richard F Gillum, Audra L Gold, Philimon Gona, Rajeev Gupta, Tesfa Dejenie Habtewold, Nima Hafezi‐Nejad, Tesfayé Hailu, Gessessew Bugssa Hailu, Graeme J. Hankey, Hamid Yimam Hassen, Kalkidan Hassen Abate, Rasmus Havmoeller, Simon I Hay, Masako Horino, Peter J. Hotez, Kathryn H. Jacobsen, Spencer L James, Mehdi Javanbakht, Panniyammakal Jeemon, Denny John, Jost B. Jonas, Yogeshwar Kalkonde, Chanté Karimkhani, Amir Kasaeian, Yousef Khader, Abdur Rahman Khan, Young‐Ho Khang, Sahil Khera, Abdullah T Khoja, Jagdish Khubchandani, Daniel Kim, Dhaval Kolte, Soewarta Kosen, Kristopher J Krohn, G Anil Kumar, Gene F. Kwan, Dharmesh Kumar Lal, Anders Larsson, Shai Linn, Alan D Lopez, Paulo A. Lotufo, Hassan Magdy Abd El Razek

BACKGROUND: The burden of cardiovascular diseases (CVDs) remains unclear in many regions of the world. OBJECTIVES: The GBD (Global Burden of Disease) 2015 study integrated data on disease incidence, prevalence, and mortality to produce consistent, up-to-date estimates for cardiovascular burden. METHODS: CVD mortality was estimated from vital registration and verbal autopsy data. CVD prevalence was estimated using modeling software and data from health surveys, prospective cohorts, health system administrative data, and registries. Years lived with disability (YLD) were estimated by multiplying prevalence by disability weights. Years of life lost (YLL) were estimated by multiplying age-specific CVD deaths by a reference life expectancy. A sociodemographic index (SDI) was created for each location based on income per capita, educational attainment, and fertility. RESULTS: In 2015, there were an estimated 422.7 million cases of CVD (95% uncertainty interval: 415.53 to 427.87 million cases) and 17.92 million CVD deaths (95% uncertainty interval: 17.59 to 18.28 million CVD deaths). Declines in the age-standardized CVD death rate occurred between 1990 and 2015 in all high-income and some middle-income countries. Ischemic heart disease was the leading cause of CVD health lost globally, as well as in each world region, followed by stroke. As SDI increased beyond 0.25, the highest CVD mortality shifted from women to men. CVD mortality decreased sharply for both sexes in countries with an SDI >0.75. CONCLUSIONS: CVDs remain a major cause of health loss for all regions of the world. Sociodemographic change over the past 25 years has been associated with dramatic declines in CVD in regions with very high SDI, but only a gradual decrease or no change in most regions. Future updates of the GBD study can be used to guide policymakers who are focused on reducing the overall burden of noncommunicable disease and achieving specific global health targets for CVD.

View all 10 publications